Report cover image

Global Platinum-based Antineoplastic Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 118 Pages
SKU # APRC20353918

Description

Summary

According to APO Research, The global Platinum-based Antineoplastic market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Platinum-based Antineoplastic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Platinum-based Antineoplastic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Platinum-based Antineoplastic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Platinum-based Antineoplastic include ChiTaiTianQing Pharmaceutical Group, Simcere Pharmaceutical, CSPC Pharmaceutical Group, Sanofi, Novartis, MSD, Roche, Pfizer and Hengrui Medicine, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Platinum-based Antineoplastic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Platinum-based Antineoplastic.

The Platinum-based Antineoplastic market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Platinum-based Antineoplastic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Platinum-based Antineoplastic Segment by Company

ChiTaiTianQing Pharmaceutical Group
Simcere Pharmaceutical
CSPC Pharmaceutical Group
Sanofi
Novartis
MSD
Roche
Pfizer
Hengrui Medicine
Hansoh Pharmaceutical Group
GSK
Bristol-Myers Squibb
Abbvie
AstraZeneca
Asta Medica GmbH

Platinum-based Antineoplastic Segment by Type

Oxaliplatin
Cycloplatin
Carboplatin
Lobaplatin
Nedaplatin
Cisplatin

Platinum-based Antineoplastic Segment by Application

Targeted Therapy
Monotherapy
Combination Therapy

Platinum-based Antineoplastic Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Antineoplastic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Antineoplastic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Antineoplastic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Platinum-based Antineoplastic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

118 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Platinum-based Antineoplastic Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Platinum-based Antineoplastic Sales Estimates and Forecasts (2020-2031)
1.3 Platinum-based Antineoplastic Market by Type
1.3.1 Oxaliplatin
1.3.2 Cycloplatin
1.3.3 Carboplatin
1.3.4 Lobaplatin
1.3.5 Nedaplatin
1.3.6 Cisplatin
1.4 Global Platinum-based Antineoplastic Market Size by Type
1.4.1 Global Platinum-based Antineoplastic Market Size Overview by Type (2020-2031)
1.4.2 Global Platinum-based Antineoplastic Historic Market Size Review by Type (2020-2025)
1.4.3 Global Platinum-based Antineoplastic Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Platinum-based Antineoplastic Sales Breakdown by Type (2020-2025)
1.5.2 Europe Platinum-based Antineoplastic Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Platinum-based Antineoplastic Sales Breakdown by Type (2020-2025)
1.5.4 South America Platinum-based Antineoplastic Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Platinum-based Antineoplastic Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Platinum-based Antineoplastic Industry Trends
2.2 Platinum-based Antineoplastic Industry Drivers
2.3 Platinum-based Antineoplastic Industry Opportunities and Challenges
2.4 Platinum-based Antineoplastic Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Platinum-based Antineoplastic Revenue (2020-2025)
3.2 Global Top Players by Platinum-based Antineoplastic Sales (2020-2025)
3.3 Global Top Players by Platinum-based Antineoplastic Price (2020-2025)
3.4 Global Platinum-based Antineoplastic Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Platinum-based Antineoplastic Major Company Production Sites & Headquarters
3.6 Global Platinum-based Antineoplastic Company, Product Type & Application
3.7 Global Platinum-based Antineoplastic Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Platinum-based Antineoplastic Market CR5 and HHI
3.8.2 Global Top 5 and 10 Platinum-based Antineoplastic Players Market Share by Revenue in 2024
3.8.3 2023 Platinum-based Antineoplastic Tier 1, Tier 2, and Tier 3
4 Platinum-based Antineoplastic Regional Status and Outlook
4.1 Global Platinum-based Antineoplastic Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Platinum-based Antineoplastic Historic Market Size by Region
4.2.1 Global Platinum-based Antineoplastic Sales in Volume by Region (2020-2025)
4.2.2 Global Platinum-based Antineoplastic Sales in Value by Region (2020-2025)
4.2.3 Global Platinum-based Antineoplastic Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Platinum-based Antineoplastic Forecasted Market Size by Region
4.3.1 Global Platinum-based Antineoplastic Sales in Volume by Region (2026-2031)
4.3.2 Global Platinum-based Antineoplastic Sales in Value by Region (2026-2031)
4.3.3 Global Platinum-based Antineoplastic Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Platinum-based Antineoplastic by Application
5.1 Platinum-based Antineoplastic Market by Application
5.1.1 Targeted Therapy
5.1.2 Monotherapy
5.1.3 Combination Therapy
5.2 Global Platinum-based Antineoplastic Market Size by Application
5.2.1 Global Platinum-based Antineoplastic Market Size Overview by Application (2020-2031)
5.2.2 Global Platinum-based Antineoplastic Historic Market Size Review by Application (2020-2025)
5.2.3 Global Platinum-based Antineoplastic Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Platinum-based Antineoplastic Sales Breakdown by Application (2020-2025)
5.3.2 Europe Platinum-based Antineoplastic Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Platinum-based Antineoplastic Sales Breakdown by Application (2020-2025)
5.3.4 South America Platinum-based Antineoplastic Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Platinum-based Antineoplastic Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 ChiTaiTianQing Pharmaceutical Group
6.1.1 ChiTaiTianQing Pharmaceutical Group Comapny Information
6.1.2 ChiTaiTianQing Pharmaceutical Group Business Overview
6.1.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.1.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.1.5 ChiTaiTianQing Pharmaceutical Group Recent Developments
6.2 Simcere Pharmaceutical
6.2.1 Simcere Pharmaceutical Comapny Information
6.2.2 Simcere Pharmaceutical Business Overview
6.2.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
6.2.5 Simcere Pharmaceutical Recent Developments
6.3 CSPC Pharmaceutical Group
6.3.1 CSPC Pharmaceutical Group Comapny Information
6.3.2 CSPC Pharmaceutical Group Business Overview
6.3.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.3.5 CSPC Pharmaceutical Group Recent Developments
6.4 Sanofi
6.4.1 Sanofi Comapny Information
6.4.2 Sanofi Business Overview
6.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
6.4.5 Sanofi Recent Developments
6.5 Novartis
6.5.1 Novartis Comapny Information
6.5.2 Novartis Business Overview
6.5.3 Novartis Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Novartis Platinum-based Antineoplastic Product Portfolio
6.5.5 Novartis Recent Developments
6.6 MSD
6.6.1 MSD Comapny Information
6.6.2 MSD Business Overview
6.6.3 MSD Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.6.4 MSD Platinum-based Antineoplastic Product Portfolio
6.6.5 MSD Recent Developments
6.7 Roche
6.7.1 Roche Comapny Information
6.7.2 Roche Business Overview
6.7.3 Roche Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Roche Platinum-based Antineoplastic Product Portfolio
6.7.5 Roche Recent Developments
6.8 Pfizer
6.8.1 Pfizer Comapny Information
6.8.2 Pfizer Business Overview
6.8.3 Pfizer Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pfizer Platinum-based Antineoplastic Product Portfolio
6.8.5 Pfizer Recent Developments
6.9 Hengrui Medicine
6.9.1 Hengrui Medicine Comapny Information
6.9.2 Hengrui Medicine Business Overview
6.9.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
6.9.5 Hengrui Medicine Recent Developments
6.10 Hansoh Pharmaceutical Group
6.10.1 Hansoh Pharmaceutical Group Comapny Information
6.10.2 Hansoh Pharmaceutical Group Business Overview
6.10.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.10.5 Hansoh Pharmaceutical Group Recent Developments
6.11 GSK
6.11.1 GSK Comapny Information
6.11.2 GSK Business Overview
6.11.3 GSK Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.11.4 GSK Platinum-based Antineoplastic Product Portfolio
6.11.5 GSK Recent Developments
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Comapny Information
6.12.2 Bristol-Myers Squibb Business Overview
6.12.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments
6.13 Abbvie
6.13.1 Abbvie Comapny Information
6.13.2 Abbvie Business Overview
6.13.3 Abbvie Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Abbvie Platinum-based Antineoplastic Product Portfolio
6.13.5 Abbvie Recent Developments
6.14 AstraZeneca
6.14.1 AstraZeneca Comapny Information
6.14.2 AstraZeneca Business Overview
6.14.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.14.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
6.14.5 AstraZeneca Recent Developments
6.15 Asta Medica GmbH
6.15.1 Asta Medica GmbH Comapny Information
6.15.2 Asta Medica GmbH Business Overview
6.15.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
6.15.5 Asta Medica GmbH Recent Developments
7 North America by Country
7.1 North America Platinum-based Antineoplastic Sales by Country
7.1.1 North America Platinum-based Antineoplastic Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Platinum-based Antineoplastic Sales by Country (2020-2025)
7.1.3 North America Platinum-based Antineoplastic Sales Forecast by Country (2026-2031)
7.2 North America Platinum-based Antineoplastic Market Size by Country
7.2.1 North America Platinum-based Antineoplastic Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Platinum-based Antineoplastic Market Size by Country (2020-2025)
7.2.3 North America Platinum-based Antineoplastic Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Platinum-based Antineoplastic Sales by Country
8.1.1 Europe Platinum-based Antineoplastic Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Platinum-based Antineoplastic Sales by Country (2020-2025)
8.1.3 Europe Platinum-based Antineoplastic Sales Forecast by Country (2026-2031)
8.2 Europe Platinum-based Antineoplastic Market Size by Country
8.2.1 Europe Platinum-based Antineoplastic Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Platinum-based Antineoplastic Market Size by Country (2020-2025)
8.2.3 Europe Platinum-based Antineoplastic Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Platinum-based Antineoplastic Sales by Country
9.1.1 Asia-Pacific Platinum-based Antineoplastic Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Platinum-based Antineoplastic Sales by Country (2020-2025)
9.1.3 Asia-Pacific Platinum-based Antineoplastic Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Platinum-based Antineoplastic Market Size by Country
9.2.1 Asia-Pacific Platinum-based Antineoplastic Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Platinum-based Antineoplastic Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Platinum-based Antineoplastic Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Platinum-based Antineoplastic Sales by Country
10.1.1 South America Platinum-based Antineoplastic Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Platinum-based Antineoplastic Sales by Country (2020-2025)
10.1.3 South America Platinum-based Antineoplastic Sales Forecast by Country (2026-2031)
10.2 South America Platinum-based Antineoplastic Market Size by Country
10.2.1 South America Platinum-based Antineoplastic Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Platinum-based Antineoplastic Market Size by Country (2020-2025)
10.2.3 South America Platinum-based Antineoplastic Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Platinum-based Antineoplastic Sales by Country
11.1.1 Middle East and Africa Platinum-based Antineoplastic Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Platinum-based Antineoplastic Sales by Country (2020-2025)
11.1.3 Middle East and Africa Platinum-based Antineoplastic Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Platinum-based Antineoplastic Market Size by Country
11.2.1 Middle East and Africa Platinum-based Antineoplastic Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Platinum-based Antineoplastic Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Platinum-based Antineoplastic Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Platinum-based Antineoplastic Value Chain Analysis
12.1.1 Platinum-based Antineoplastic Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Platinum-based Antineoplastic Production Mode & Process
12.2 Platinum-based Antineoplastic Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Platinum-based Antineoplastic Distributors
12.2.3 Platinum-based Antineoplastic Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.